184 related articles for article (PubMed ID: 34865635)
21. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia.
Antonio Buendía J; Patiño DG
Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):575-580. PubMed ID: 34860616
[TBL] [Abstract][Full Text] [Related]
24. The cost-effectiveness of as-needed budesonide/formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in the UK.
FitzGerald JM; Arnetorp S; Smare C; Gibson D; Coulton K; Hounsell K; Golam S; Sadatsafavi M
Respir Med; 2020 Sep; 171():106079. PubMed ID: 32917353
[TBL] [Abstract][Full Text] [Related]
25. Cost utility of vitamin D supplementation in adults with mild to moderate asthma.
Antonio Buendía J; Rodriguez-Martinez CE; Sossa-Briceño MP
J Asthma; 2023 May; 60(5):951-959. PubMed ID: 35920247
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial.
Wilson EC; Sims EJ; Musgrave SD; Shepstone L; Blyth A; Murdoch J; Mugford HM; Juniper EF; Ayres JG; Wolfe S; Freeman D; Gilbert RF; Harvey I; Hillyer EV; Price D
Pharmacoeconomics; 2010; 28(7):585-95. PubMed ID: 20550224
[TBL] [Abstract][Full Text] [Related]
27. Cost Utility of Intermittent Inhaled Corticosteroids in Preschoolers with Viral-Triggered Wheeze.
Buendía JA; Guerrero Patiño D; Giraldo Ramírez JE
Pediatr Allergy Immunol Pulmonol; 2022 Mar; 35(1):36-42. PubMed ID: 35320007
[No Abstract] [Full Text] [Related]
28. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
van Boven JF; Kocks JW; Postma MJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
[TBL] [Abstract][Full Text] [Related]
29. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
[TBL] [Abstract][Full Text] [Related]
30. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.
Main C; Shepherd J; Anderson R; Rogers G; Thompson-Coon J; Liu Z; Hartwell D; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(20):1-174, iii-iv. PubMed ID: 18485272
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Tiotropium in Elderly Patients with Severe Asthma Using Real-World Data.
Hong SH; Cho JY; Kim TB; Lee EK; Kwon SH; Shin JY
J Allergy Clin Immunol Pract; 2021 May; 9(5):1939-1947.e7. PubMed ID: 33307277
[TBL] [Abstract][Full Text] [Related]
32. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β
Pavord ID; Mathieson N; Scowcroft A; Pedersini R; Isherwood G; Price D
NPJ Prim Care Respir Med; 2017 Mar; 27(1):17. PubMed ID: 28270657
[TBL] [Abstract][Full Text] [Related]
33. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
Mangia PP; Gallo O; Ritrovato D; Pradelli L
Clin Drug Investig; 2021 Sep; 41(9):785-794. PubMed ID: 34333742
[TBL] [Abstract][Full Text] [Related]
34. Long-Acting β-Agonist in Combination or Separate Inhaler as Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids.
Turner S; Richardson K; Murray C; Thomas M; Hillyer EV; Burden A; Price DB;
J Allergy Clin Immunol Pract; 2017; 5(1):99-106.e3. PubMed ID: 27421902
[TBL] [Abstract][Full Text] [Related]
35. Cost-utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients.
Rodriguez-Martinez CE; Sossa-Briceño MP; Castro-Rodriguez JA
J Asthma; 2016 Jun; 53(5):538-45. PubMed ID: 26786524
[TBL] [Abstract][Full Text] [Related]
36. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.
Bamrungsawad N; Chaiyakunapruk N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P
Pharmacoeconomics; 2015 May; 33(5):521-31. PubMed ID: 25774016
[TBL] [Abstract][Full Text] [Related]
37. Health and cost impact of stepping down asthma medication for UK patients, 2001-2017: A population-based observational study.
Bloom CI; de Preux L; Sheikh A; Quint JK
PLoS Med; 2020 Jul; 17(7):e1003145. PubMed ID: 32692744
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
[TBL] [Abstract][Full Text] [Related]
39. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.
Dalon F; Roche N; Belhassen M; Nolin M; Pegliasco H; Deslée G; Housset B; Devillier P; Van Ganse E
Int J Chron Obstruct Pulmon Dis; 2019; 14():1839-1854. PubMed ID: 31692478
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
Doull I; Price D; Thomas M; Hawkins N; Stamuli E; Tabberer M; Gosden T; Rudge H
Curr Med Res Opin; 2007 May; 23(5):1147-59. PubMed ID: 17519082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
